Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Amarantus Bioscience Holdings, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 | 5 | 2 |
| Amarantus Bioscience Holdings, Inc., Medical Equipment Deals By Type, 2010 to YTD 2016 | 7 | 1 |
| Amarantus Bioscience Holdings, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 | 8 | 1 |
| Amarantus Bioscience Holdings, Inc., Medical Equipment, Deals By Market, 2010 to YTD 2016 | 9 | 1 |
| Amarantus Bioscience Holdings, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016 | 10 | 1 |
| Amarantus Bioscience Holdings, Inc., Medical Equipment, Deal Details | 11 | 14 |
| Asset Purchase | 11 | 1 |
| Amarantus Bioscience Acquires Rights To LymPro Test From Memory Dx | 11 | 2 |
| Amarantus BioScience Acquires Intellectual Property Portfolio From Power3 Medical Products | 13 | 2 |
| Venture Financing | 15 | 1 |
| Cerora Raises Additional Funds through Second Closing of Seed Financing | 15 | 1 |
| Partnerships | 16 | 1 |
| Amarantus BioSciences Exercises Option For Licensing Agreement With Memory Dx For Alzheimer's Diagnostic Blood Test | 16 | 2 |
| Amarantus BioSciences Enters Into Licensing Agreement With Power3 Medical Products | 18 | 2 |
| Generex Biotech Enters Into Licensing Agreement With Amarantus BioSciences | 20 | 2 |
| Equity Offering | 22 | 1 |
| Amarantus Bioscience Raises USD5 Million in Private Placement of Series G Preferred Stock | 22 | 1 |
| Acquisition | 23 | 1 |
| Avant Diagnostics Acquires Amarantus Diagnostics | 23 | 1 |
| Amarantus BioScience Acquires DioGenix | 24 | 1 |
| Amarantus Bioscience Holdings, Inc. - Key Competitors | 25 | 1 |
| Key Employees | 26 | 1 |
| Locations And Subsidiaries | 27 | 1 |
| Head Office | 27 | 1 |
| Other Locations &Subsidiaries | 27 | 1 |
| Recent Developments | 28 | 1 |
| Financial Announcements | 28 | 1 |
| Jun 03, 2016: Amarantus Announces Fiscal Year 2015 and First Quarter 2016 Financial Results | 28 | 2 |
| Aug 17, 2015: Amarantus Reports Second Quarter 2015 Financial Results and Business Overview | 30 | 3 |
| May 20, 2015: Amarantus Reports First Quarter 2015 Financial Results and Business Overview | 33 | 2 |
| Apr 07, 2015: Amarantus Reports 2014 Financial Results and Business Overview | 35 | 3 |
| Corporate Communications | 38 | 1 |
| Jul 27, 2015: Amarantus Diagnostics Establishes Strategic Advisory Committee | 38 | 2 |
| Jul 13, 2015: Amarantus to Commence Trading on the OTCQX Marketplace Under Existing Ticker Symbol AMBS | 40 | 1 |
| Jan 22, 2015: Amarantus Forms Alzheimer's Disease Diagnostics Scientific Advisory Board | 41 | 2 |
| Product News | 43 | 1 |
| Aug 06, 2015: Researchers Funded by the National MS Society Build on Commercial Partnership to Develop Diagnostic Test for MS | 43 | 1 |
| May 11, 2015: Amarantus Reports Preliminary Data From Blood-based Version of MSPrecise Diagnostic for Multiple Sclerosis | 44 | 1 |
| Mar 23, 2015: Amarantus to Present at the Neurotech Investing and Partnering Conference on Tuesday, April 7, 2015 | 45 | 1 |
| Feb 18, 2015: Amarantus Announces First Alzheimer s Biomarker Services Collaboration for LymPro Test with Anavex Life Sciences | 46 | 2 |
| Jan 15, 2015: Amarantus Announces Positive Data From 140 Subject LP-002 Clinical Study of LymPro Test Confirming Statistically Significant Markers for Alzheimer's | 48 | 1 |
| Clinical Trials | 49 | 1 |
| May 11, 2015: Amarantus Reports Preliminary Data From Blood-based Version of MSPrecise Diagnostic for Multiple Sclerosis | 49 | 1 |
| Jan 15, 2015: Amarantus Announces Positive Data From 140 Subject LP-002 Clinical Study of LymPro Test Confirming Statistically Significant Markers for Alzheimer's | 50 | 1 |
| Other Significant Developments | 51 | 1 |
| Feb 22, 2016: Amarantus and Lonza Walkersville Provide Update on cGMP Manufacturing Readiness for the Engineered Skin Substitute Program | 51 | 1 |
| 7 Feb 18, 2015: Amarantus Announces First Alzheimer's Biomarker Services Collaboration for LymPro Test With Anavex Life Sciences | 51 | 2 |
| Appendix | 53 | 1 |
| Methodology | 53 | 1 |
| About GlobalData | 53 | 1 |
| Contact Us | 53 | 1 |
| Disclaimer | 53 | 1 |